A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden
Authors:
- Michael WillisMWMichael Willis
- Knut ÖdegaardKÖKnut Ödegaard
- Ulf PerssonUPUlf Persson
- 1 January 2001
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 21 (2) , 115-127
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Lifetime Risk of Hip Fractures is UnderestimatedOsteoporosis International, 1998
- Epidemiology and predictors of fractures associated with osteoporosisThe American Journal of Medicine, 1997
- The crippling consequences of fractures and their impact on quality of lifeThe American Journal of Medicine, 1997
- Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis FoundationJournal of Bone and Mineral Research, 1997
- Perspectives: How many women have osteoporosis now?Journal of Bone and Mineral Research, 1995
- Hormone Replacement TherapyPharmacoEconomics, 1994
- Cost‐effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fractureAustralian Journal of Public Health, 1994
- Postmenopausal hot flushes and their managementPharmacology & Therapeutics, 1993
- The normal menopause transitionAmerican Journal of Human Biology, 1992
- Postmenopausal Bone Loss Is Prevented by Treatment with Low-Dosage Estrogen with CalciumAnnals of Internal Medicine, 1987